Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
31.58
-0.16 (-0.50%)
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of central nervous system disorders, particularly epilepsy and attention deficit hyperactivity disorder (ADHD)
The company leverages its proprietary drug formulation technologies to create specialized medications that enhance patient outcomes. With a commitment to addressing unmet medical needs, Supernus actively engages in research and development, aiming to expand its product offerings and provide effective treatment solutions for patients suffering from these challenging conditions.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQCORT) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSEBMY) and the best and worst performers in the branded pharmaceuticals industry.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQSUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.27 per share was significantly above analysts’ consensus estimates.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQSUPN)
will be announcing earnings results tomorrow after market hours. Here’s what you need to know.
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on its future.
Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million.
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.
